Effects of transdermal testosterone treatment on inflammatory markers in elderly males

Endocrine Practice

Volumn 20, Issue 11, 2014, Pages 1170-1177

  Maggio, Marcello ^a,b   Snyder, Peter ^c   De Vita, Francesca ^b   Ceda, Gian ^a,b   Milaneschi, Yuri ^d,e   Lauretani, Fulvio ^b   Luci, Michele ^a   Cattabiani, Chiara ^a   Peachey, Helen ^c   Valenti, Giorgio ^a   Cappola, Anne ^c   Longo, Dan ^e   Ferrucci, Luigi ^e  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PLACEBO; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE ACTION; HUMAN; INFLAMMATION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; UNITED STATES; DOUBLE BLIND PROCEDURE;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; HUMANS; INTERLEUKIN-6; MALE; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84917672693     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13357.OR     Document Type: Article

References (34)

1. Basaria S. Reproductive aging in men. Endocrinol Metab Clin North Am. 2013;42:255-270.
2. Brunnsgard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol. 2001;8: 131-136.
3. Franceschi C, Bonafè M, Valensin S, et al. Inflammaging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000;908:244-254.
4. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59: 242-248.
5. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61:575-584.
6. Kahl S, Elsasser TH. Exogenous testosterone modulates tumor necrosis factor-alpha and acute phase protein responses to repeated endotoxin challenge in steers. Domest Anim Endocrinol. 2006;31:301-311.
7. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev. 1996;17:369-384.
8. Viselli SM, Stanziale S, Shults K, Kovacs WJ, Olsen NJ. Castration alters peripheral immune function in normal male mice. Immunology. 1995;84:337-342.
9. Bizzarro A, Valentini G, Di Martino G, DaPonte A, De Bellis A, Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. J Clin Endocrinol Metab. 1987;64:32-36.
10. Yesilova Z, Ozata M, Kocar IH, et al. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotrpic hypogonadism. J Clin Endocrinol Metab. 2000;85:66-70.
11. Spratt DI, Cox P, Orav J, Moloney J, Bigos T. Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab. 1993;76:1548-1554.
12. Maggio M, Ceda GP, De Cicco G, et al. Acute changes in circulating hormones in older patients with impaired ventricular function undergoing on-pump coronary artery bypass grafting. J Endocrinol Invest. 2005;28:711-719.
13. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin- 6 receptor in older men. J Clin Endocrinol Metab. 2006;91:345-347.
14. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, McKinlay JB. Association of sex hormones and C-reactive protein levels in men. Clin Endocrinol (Oxf). 2010;72:527-533.
15. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007;156:595-602.
16. Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf). 2005; 62:228-235.
17. Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2013; 68:153-160.
18. Nakhai-Pour HR, Grobbee DE, Emmelot-Vonk MH, Bots ML, Verhaar HJ, van der Schouw YT. Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial. Am Heart J. 2007;154:1228.e1-7.
19. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602-612.
20. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89: 3313-3318.
21. Giltay EJ, Haider A, Saad F, Gooren LJ. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia. 2008;40:398-400.
22. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966-1972.
23. Maggio M, Snyder PJ, Ceda GP, et al. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology. 2013; 1:24-28.
24. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165-1188.
25. Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM, Orfao A. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol. 2006;189: 595-604.
26. Guler N, Batyraliev T, Dulger H, et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol. 2006;109:339-343.
27. Singh AB, Hsia S, Alaupovic P, at al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136-143.
28. Maggio M, Blackford A, Taub D, et al. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl. 2006;27:725-728.
29. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002;87:1550-1554.
30. Saylor PJ, Kozak KR, Smith MR, et al. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012;17:212-219.
31. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318-322.
32. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 1999;33:1935-1942.
33. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55:445-451.
34. Hsing AW, Stanczyk FZ, Bélanger A, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev. 2007;16: 1004-1008.